The secrecy that has long surrounded drug-industry trials is crumbling. Scientists are applauding drug giant Glaxo­SmithKline (GSK) for its announcement last week that it will make the trove of detailed raw data underlying its clinical trials systematically available to researchers. And GSK’s move — the first such commitment for a big player in the industry — is just the beginning. Starting next year, the European Medicines Agency (EMA) intends to open up access to all new clinical-trial data sets it receives from industry for product registration.